BCM
AMAG

Breithorn Capital Management’s AMAG Pharmaceuticals AMAG Stock Holding History

Breithorn Capital Management’s Portfolio AMAG Stock Details AMAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$2.64M Buy
+143,700
New +$2.85M 1.87% 27

Other funds holding AMAG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Breithorn Capital Management's AMAG Position: Q2 2017 in Review

Breithorn Capital Management opened a new position in AMAG Pharmaceuticals (AMAG) in Q2 2017: 143,700 shares worth $2.64M. The stake represents 1.87% of the portfolio and ranks #27 among its holdings.

174 funds tracked by Wall St. Rank hold AMAG as of Q2 2017.

  • Breithorn Capital Management held 143,700 shares of AMAG Pharmaceuticals worth $2.64M as of Q2 2017.
  • AMAG Pharmaceuticals was a new Breithorn Capital Management position in Q2 2017.
  • AMAG Pharmaceuticals made up 1.87% of Breithorn Capital Management's portfolio in Q2 2017, its #27 holding.
  • 174 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q2 2017.

Based on Breithorn Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.